Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dolutegravir Plus Lamivudine (DTG/3TC) Dual Therapy Versus Dolutegravir With TDF-lamivudine (DTG + TDF/3TC) Among Antiretroviral naïve People With HIV and TB Receiving Rifampin-based TB Treatment

NCT06497465 is registered in ClinicalTrials.gov with Johns Hopkins University as lead sponsor.

NCT NCT06497465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06497465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dolutegravir Plus Lamivudine (DTG/3TC) Dual Therapy Versus Dolutegravir With TDF-lamivudine (DTG + TDF/3TC) Among Antiretroviral naïve People With HIV and TB Receiving Rifampin-based TB Treatment
Lead sponsor
Johns Hopkins University
Phase
Phase 3
Overall status
Recruiting
Start date
September 18, 2025
Completion date
January 31, 2029
Enrollment
150 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hiv, tuberculosis